Tweet
Athenex Inc (NASDAQ:ATNX) has been assigned an average recommendation of "Buy" from the nine analysts that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $26.71.
ATNX has been the topic of a number of research analyst reports. BidaskClub downgraded shares of Athenex from a "strong-buy" rating to a "buy" rating in a research note on Thursday, April 19th. ValuEngine upgraded shares of Athenex from a "sell" rating to a "hold" rating in a research note on Wednesday, May 2nd. Finally, Zacks Investment Research downgraded shares of Athenex from a "buy" rating to a "hold" rating in a research note on Wednesday, May 30th. Get Athenex alerts:
In other news, Director Song-Yi Zhang sold 70,584 shares of the stock in a transaction that occurred on Tuesday, May 29th. The shares were sold at an average price of $16.07, for a total transaction of $1,134,284.88. Following the transaction, the director now directly owns 4,000 shares in the company, valued at $64,280. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website . Also, Director Sheldon Trainor-Degirolamo sold 121,688 shares of the stock in a transaction that occurred on Wednesday, May 23rd. The shares were sold at an average price of $17.01, for a total transaction of $2,069,912.88. The disclosure for this sale can be found here . Insiders sold a total of 245,898 shares of company stock worth $4,103,732 over the last 90 days. Insiders own 29.50% of the company's stock. Several hedge funds and other institutional investors have recently added to or reduced their stakes in ATNX. BlackRock Inc. boosted its stake in shares of Athenex by 253.0% during the fourth quarter. BlackRock Inc. now owns 1,086,985 shares of the company's stock valued at $17,282,000 after purchasing an additional 779,092 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Athenex by 29.8% during the fourth quarter. Geode Capital Management LLC now owns 116,809 shares of the company's stock valued at $1,857,000 after purchasing an additional 26,833 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of Athenex by 190.8% during the fourth quarter. Deutsche Bank AG now owns 18,511 shares of the company's stock valued at $293,000 after purchasing an additional 12,146 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Athenex by 176.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 87,427 shares of the company's stock valued at $1,390,000 after purchasing an additional 55,795 shares in the last quarter. Finally, Millennium Management LLC boosted its stake in shares of Athenex by 170.1% during the fourth quarter. Millennium Management LLC now owns 64,002 shares of the company's stock valued at $1,018,000 after purchasing an additional 40,302 shares in the last quarter. Hedge funds and other institutional investors own 17.30% of the company's stock.
Shares of ATNX stock opened at $16.67 on Friday. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of -7.19 and a beta of -1.44. Athenex has a one year low of $13.28 and a one year high of $20.90.
Athenex (NASDAQ:ATNX) last issued its earnings results on Tuesday, August 14th. The company reported ($0.58) EPS for the quarter, missing the Zacks' consensus estimate of ($0.48) by ($0.10). The company had revenue of $11.57 million during the quarter. Athenex had a negative return on equity of 75.45% and a negative net margin of 136.72%. sell-side analysts anticipate that Athenex will post -1.36 earnings per share for the current fiscal year.
About Athenex
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer